{
  "source": "PA-Med-Nec-Vyndaqel-Vyndamax.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2169-8\nProgram Prior Authorization/Medical Necessity\nMedication Vyndaqel® (tafamidis meglumine) and Vyndamax™ (tafamidis)\nP&T Approval Date 6/2019, 2/2020, 2/2021, 2/2022, 2/2023, 9/2023, 9/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nVyndaqel (tafamidis meglumine) and Vyndamax™ (tafamidis) are transthyretin stabilizers\nindicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-\nmediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related\nhospitalization.\n2. Coverage Criteriaa:\nA. Transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)\n1. Initial Authorization\na. Vyndaqel/Vyndamax will be approved based on all of the following criteria:\n(1) Diagnosis of transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy\n(ATTR-CM)\n-AND-\n(2) One of the following:\n(a) Documentation that the patient has a pathogenic TTR mutation (e.g., V30M)\n-OR-\n(b) Cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of\nATTR amyloid deposits\n-OR-\n(c) All of the following:\ni. Echocardiagram or cardiac magnetic resonance imaging suggestive of\namyloidosis\n-AND-\nii. Radionuclide imaging (99mTc-DPD, 99mTc-PYP, or 99m Tc-HMDP) showing\ngrade 2 or 3 cardiac uptake*\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\niii. Absence of light chain amyloidosis\n-AND-\n(3) Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart\nfailure\n-AND-\n(4) Physician attests that the patient has an N-terminal pro-B-type naturetic peptide (NT-\nproBNP) level that, when combined with signs and symptoms, is considered\ndefinitive for a diagnosis of ATTR-CM\n-AND-\n(5) One of the following:\n(a) History of heart failure, with at least one prior hospitalization for heart failure\n-OR-\n(b) Presence of clinical signs and symptoms of heart failure (e.g., dyspnea, edema)\n-AND-\n(6) Prescribed by or in consultation with a cardiologis",
    "least one prior hospitalization for heart failure\n-OR-\n(b) Presence of clinical signs and symptoms of heart failure (e.g., dyspnea, edema)\n-AND-\n(6) Prescribed by or in consultation with a cardiologist\n-AND-\n(7) Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted\ntherapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis),\nOnpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vyndaqel/Vyndamax will be approved based on all of the following criteria:\n(1) Documentation that the patient has experienced a positive clinical response to\nVyndaqel/Vyndamax (e.g., improved symptoms, quality of life, slowing of disease\nprogression, decreased hospitalizations, etc.)\n-AND-\n(2) Documentation that patient continues to have New York Heart Association (NYHA)\nFunctional Class I, II, or III heart failure\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(3) Prescribed by or in consultation with a cardiologist\n-AND-\n(4) Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted\ntherapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis),\nOnpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n*May require prior authorization and notification\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Vyndaqel and Vyndamax [package insert]. Pfizer, Inc: New York",
    "utomated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Vyndaqel and Vyndamax [package insert]. Pfizer, Inc: New York, NY; October 2023.\n2. Mauer MS, Schwartz JH, Gundapeneni B, et al. Tafamidis treatment for patients with\ntransthyretin amyloid cardiomyopathy. N Engl J Med. 2018; 379:1007-16.\n3. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin\namyloidosis. Circulation. 2016; 133:2404-12.\n4. Mckenna WJ. Treatment of amyloid cardiomyopathy. UpToDate. Waltham, MA: UpToDate Inc.\nhttps://www.uptodate.com (Accessed on December 2, 2024.)\n5. Mckenna WJ. Clinical manifestations and diagnosis of amyloid cardiomyopathy. UpToDate.\nWaltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on December 2, 2024.)\n6. Kittleson MM, Maurer MS, et al. American Heart Association Heart Failure and Transplantation\nCommittee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and\nManagement: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul\n7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Erratum in:\nCirculation. 2021 Jul 6;144(1):e10. Erratum in: Circulation. 2021 Jul 6;144(1):e11. PMID:\n32476490.\nKittleson MM, Ruberg FL, et al. 2023 ACC Expert Consensus Decision Pathway on\nComprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the\nAmerican College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023\nMar 21;81(11):1076-1126.\n© 2025 UnitedHealthcare Services, Inc.\n3\nProgram Prior Authorization/Medical Necessity - Vyndaqel® (tafamidis meglumine)\nand Vyndamax™ (tafamidis)\nChange Control\n6/2019 New program.\n2/2020 Updated program to address potential combination amyloidosis treatment.\n2/2021 Annual review with no change to coverage criteria. Updated references.\n2/2022 Annual review with no change to clinical criteria. Updated references.\n2/",
    "ential combination amyloidosis treatment.\n2/2021 Annual review with no change to coverage criteria. Updated references.\n2/2022 Annual review with no change to clinical criteria. Updated references.\n2/2023 Annual review with no change to coverage criteria.\n9/2023 Added reference to support requirement that Vyndamax/Vyndaqel are not\nused in combination with another agent for cardiac amyloidosis.\n9/2024 Annual review. Renamed and added examples of RNA-targeted therapies\nfor ATTR amyloidosis.Updated and added references.\n1/2025 Annual review. Updated clinical criteria for diagnosis of ATTR cardiac\namyloidosis. Removed criteria allowing for temporary combination\ntherapy. Added examples of RNA-targeted therapy. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}